Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus

Table 1 Summary of results for HRSV F mutations.

Mutation	Processing	Percent binding			Fusion activity
		ch101F	palivizumab	mAb19
Wild-type	Complete	99.9	100.0	99.9	1.0 ± 0.0
K272M	Complete	126.6	3.8	100.5	2.3 ± 0.7
K272N	Complete	95.5	15.3	62.3	2.2 ± 0.5
K272Q	Complete	85.3	30.1	88.7	2.6 ± 0.1
K272T	Complete	70.4	9.1	68.0	1.0 ± 0.1
S275F	Complete	29.4	10.9	31.7	1.6 ± 0.2
T400A	Complete	155.2	126.6	161.2	2.9 ± 0.5
C422S	Complete	159.6	177.5	193.9	1.6 ± 0.6
N428D	Complete	116.2	139.4	121.3	0.75 ± 0.02
N428Q	Complete	117.2	190.2	193.8	1.5 ± 0.02
R429K	Complete	44.6	88.8	11.2	4.0 ± 0.2
R429S	Complete	72.5	150.0	3.9	1.1 ± 0.1
G430A	Complete	79.7	166.5	0.15	1.2 ± 0.2
I431A	Complete	61.9	108.2	81.8	1.6 ± 0.3
I431L	Complete	78.5	80.9	65.5	1.8 ± 0.1
I432L	Complete	74.9	68.9	64.4	1.5 ± 0.2
I432Q	Complete	49.3	60.8	57.9	0.7 ± 0.07
I432T	Complete	191.7	206.9	169.8	1.4 ± 0.3
K433D	Complete	1.1	29.9	1.6	0.4 ± 0.01
K433L	Complete	3.8	88.1	24.5	0.5 ± 0.1
K433N	Complete	2.9	80.7	28.7	2.2 ± 0.5
K433Q	Complete	2.7	60.7	47.4	1.0 ± 0.8
K433R	Complete	-0.6	15.8	23.1	2.0 ± 0.6
K433T	Complete	3.9	64.5	64.4	0.6 ± 0.04
K433S	Complete	69.5	86.3	111.8	0.98 ± 0.19

Processing is defined as relative amounts of F0, F1, and F2, and is described as being equivalent to wild-type HRSV F protein (complete) or reduced. Reactivity with neutralizing mAbs (palivizumab, Mab19, and ch101F) as determined by flow cytometry is reported as percent relative to wild-type HRSV F protein. Cell fusion activity (luciferase activity) is reported relative to wild-type as described in [30]. All values are expressed as relative to wild-type.

ISSN: 1743-422X